{Reference Type}: Letter
{Title}: Real-world clinical study of trastuzumab biosimilar (Zercepac) and pertuzumab (Perjeta) in combination with chemotherapy for neoadjuvant treatment of HER-2-positive breast cancer.
{Author}: Bao YF;Yang JZ;Li XF;Zhu JJ;
{Journal}: Asian J Surg
{Volume}: 47
{Issue}: 7
{Year}: 2024 Jul 23
{Factor}: 2.808
{DOI}: 10.1016/j.asjsur.2024.03.063